Meta-analysis of 10 RCTs (4329 patients with head and neck cancer): cetuximab plus radiotherapy carried a higher risk of oral mucositis than cisplatin plus radiotherapy (RR 1.15, 95% CI 1.03–1.29; I² 0%; moderate certainty).
Meta-analysisn = 4,329
Costa et al. Cetuximab increases the risk of oral mucositis in radiotherapy-treated head and neck cancer compared to cisplatin: a systematic review of randomized controlled clinical trials